和元生物
(688238)
| 流通市值：36.55亿 | | | 总市值：37.00亿 |
| 流通股本：6.41亿 | | | 总股本：6.49亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 360,037,212.35 | 439,444,851.83 | 344,381,917.11 | 486,008,211.47 |
| 应收票据及应收账款 | 85,004,384.18 | 78,038,792.58 | 69,088,038.07 | 68,000,210.89 |
| 其中：应收票据 | 1,164,000 | - | - | - |
| 应收账款 | 83,840,384.18 | 78,038,792.58 | 69,088,038.07 | 68,000,210.89 |
| 预付款项 | 6,858,981.61 | 7,667,962.11 | 9,620,975.51 | 7,840,289.13 |
| 其他应收款合计 | 642,930.15 | 409,744.19 | 2,052,365.77 | 1,986,375.12 |
| 存货 | 73,006,042.05 | 73,753,219.25 | 80,247,136.18 | 82,889,439.9 |
| 合同资产 | 21,460,087.74 | 21,110,474.52 | 33,454,877.8 | 27,287,035.73 |
| 其他流动资产 | 44,502,616.67 | 39,742,359.58 | 118,728,993.42 | 103,722,690.89 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 611,596,287.16 | 690,426,516.75 | 737,574,303.86 | 777,734,253.13 |
| 非流动资产: | | | | |
| 长期股权投资 | 66,609,731.2 | 66,340,995.43 | 66,641,541.73 | 67,309,632.71 |
| 其他权益工具投资 | 49,391,160 | 48,499,140.56 | 52,022,085.28 | 50,453,227.48 |
| 固定资产 | 1,298,357,300.14 | 1,317,694,551.8 | 1,332,193,718.51 | 1,355,164,998.61 |
| 在建工程 | 79,075,165.05 | 71,190,701.86 | 61,947,374.4 | 68,527,645.41 |
| 使用权资产 | 884,001.9 | 944,274.75 | 1,004,547.6 | 28,942,027.47 |
| 无形资产 | 54,484,912.22 | 54,985,874.12 | 55,323,721.3 | 54,647,250.77 |
| 长期待摊费用 | 4,232,375.76 | 4,912,509.15 | 8,685,043.2 | 36,479,329 |
| 递延所得税资产 | 29,719,785.77 | 29,746,176.6 | 37,908,516.35 | 43,256,989.39 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,582,754,432.04 | 1,594,314,224.27 | 1,615,726,548.37 | 1,704,781,100.84 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,194,350,719.2 | 2,284,740,741.02 | 2,353,300,852.23 | 2,482,515,353.97 |
| 流动负债: | | | | |
| 短期借款 | 180,747,694.41 | 70,051,333.34 | 70,042,000.01 | 60,040,000 |
| 应付票据及应付账款 | 117,117,349.82 | 182,816,057.52 | 153,989,198.17 | 186,625,153.11 |
| 其中：应付票据 | 486,000 | 486,000 | - | 195,618 |
| 应付账款 | 116,631,349.82 | 182,330,057.52 | 153,989,198.17 | 186,429,535.11 |
| 合同负债 | 25,416,589.53 | 30,091,175.18 | 25,684,363.49 | 29,080,945.31 |
| 应付职工薪酬 | 12,859,089.52 | 16,567,958.07 | 11,845,327.46 | 12,444,762.4 |
| 应交税费 | 2,279,148.03 | 3,163,983 | 2,528,819.75 | 2,166,432.45 |
| 其他应付款合计 | 8,019,165.78 | 7,533,710.39 | 6,571,648.27 | 6,280,569.66 |
| 一年内到期的非流动负债 | 17,799,487.9 | 17,816,184.11 | 17,689,394.59 | 25,519,906.58 |
| 其他流动负债 | 1,564,806.94 | 1,850,653.34 | 1,594,318.94 | 1,826,685.83 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 365,803,331.93 | 329,891,054.95 | 289,945,070.68 | 323,984,455.34 |
| 非流动负债: | | | | |
| 长期借款 | 119,304,500 | 126,788,000 | 128,021,500 | 135,505,000 |
| 租赁负债 | 718,264.23 | 781,160.4 | 952,776.43 | 25,819,427.07 |
| 预计负债 | 25,675,274 | 26,785,386.29 | 950,890.03 | 2,435,131.45 |
| 递延收益 | 60,164,615.58 | 60,711,555.46 | 65,085,784.08 | 47,049,195.75 |
| 递延所得税负债 | 221,823.21 | 236,068.69 | 251,136.91 | 4,447,786.17 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 206,084,477.02 | 215,302,170.84 | 195,262,087.45 | 215,256,540.44 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 571,887,808.95 | 545,193,225.79 | 485,207,158.13 | 539,240,995.78 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 649,036,700 | 649,036,700 | 647,433,100 | 647,433,100 |
| 资本公积 | 1,448,366,184.51 | 1,448,399,300.14 | 1,446,298,584.14 | 1,446,298,584.14 |
| 减:库存股 | 58,424,632.46 | - | - | - |
| 其他综合收益 | -47,282.65 | -930,684.14 | -613,128.05 | -2,079,415.32 |
| 盈余公积 | 9,313,913.89 | 9,313,913.89 | 9,313,913.89 | 9,313,913.89 |
| 未分配利润 | -425,504,302.46 | -366,027,001.02 | -233,980,756.62 | -157,559,377.05 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,622,740,580.83 | 1,739,792,228.87 | 1,868,451,713.36 | 1,943,406,805.66 |
| 少数股东权益 | -277,670.58 | -244,713.64 | -358,019.26 | -132,447.47 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,622,462,910.25 | 1,739,547,515.23 | 1,868,093,694.1 | 1,943,274,358.19 |
| 负债和股东权益合计 | 2,194,350,719.2 | 2,284,740,741.02 | 2,353,300,852.23 | 2,482,515,353.97 |
| 公告日期 | 2025-04-24 | 2025-04-18 | 2024-10-24 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |